MedTrace Logo

A Clinical Study of Xenetix 300 in Multislice Computed Tomography (CT) Pediatric Indications

NCT00347022 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 145

Last updated 2013-04-09

Study results available
· View outcomes & findings →

Summary

This is a clinical study of Xenetix 300 in Multislice Computed Tomography (MSCT) in pediatric indications.

Conditions

  • Diagnostic Imaging

Interventions

DRUG

Xenetix

300 mg of iodine/ml

DRUG

Visipaque

270 mg of iodine/ml

Sponsors & Collaborators

  • Guerbet

    lead INDUSTRY

Principal Investigators

  • Corinne Dubourdieu, PhD · Guerbet

Study Design

Allocation
RANDOMIZED
Purpose
DIAGNOSTIC
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
1 Year
Max Age
16 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-05-31
Primary Completion
2009-04-30
Completion
2009-06-30

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00347022 on ClinicalTrials.gov